Literature DB >> 8482194

Serum pepsinogens after interruption of long-term maintenance therapy with omeprazole in patients with reflux esophagitis.

I Biemond1, E C Klinkenberg-Knol, C B Lamers, S G Meuwissen.   

Abstract

Administration of omeprazole induces increases in serum concentrations of pepsinogens A and C. In 10 patients with reflux esophagitis who were on continuous maintenance treatment, the effect of cessation of omeprazole administration on serum pepsinogens was studied. Pepsinogens A and C were measured in serum samples on days 0, 1, 2, 4, 7, and 9 after treatment and the results were compared with the values available in eight patients at a time before omeprazole treatment. Serum pepsinogen A levels decreased gradually after cessation of omeprazole administration, and all values fell into the normal range after the seventh day of the study period, but were still higher than before therapy. Seven of 10 patients showed a decrease of pepsinogen C after nine days, but two patients had still increased levels at the end of the study period. The pepsinogen A:C ratio on the ninth day after cessation was significantly lower than on day 0 during omeprazole therapy. We conclude that long-term maintenance therapy with omeprazole induces significant increases in both serum pepsinogens. After cessation of omeprazole treatment, serum pepsinogens rapidly decrease in most patients, but continue to be higher before therapy for at least nine days.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8482194     DOI: 10.1007/bf01295923

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  A nongastrin malignant ampullary tumor causing gastric acid and pepsin hypersecretion. A case report.

Authors:  D D Sloas; B I Hirschowitz; W Y Chey
Journal:  J Clin Gastroenterol       Date:  1990-10       Impact factor: 3.062

2.  Effect of intermittent weekend therapy with omeprazole on basal and postprandial serum gastrin concentrations in patients with duodenal ulcer.

Authors:  L F Crobach; J B Jansen; C B Lamers
Journal:  Clin Pharmacol Ther       Date:  1988-06       Impact factor: 6.875

3.  New aspects of the trophic action of gastrointestinal hormones.

Authors:  L R Johnson
Journal:  Gastroenterology       Date:  1977-04       Impact factor: 22.682

4.  Effect of oral omeprazole on serum gastrin and serum pepsinogen I levels.

Authors:  H P Festen; J C Thijs; C B Lamers; J M Jansen; G Pals; R R Frants; J Défize; S G Meuwissen
Journal:  Gastroenterology       Date:  1984-11       Impact factor: 22.682

5.  Radioimmunoassay of human pepsinogen A and pepsinogen C.

Authors:  I Biemond; J B Jansen; L F Crobach; J Kreuning; C B Lamers
Journal:  J Clin Chem Clin Biochem       Date:  1989-01

6.  Toxicological studies on omeprazole.

Authors:  L Ekman; E Hansson; N Havu; E Carlsson; C Lundberg
Journal:  Scand J Gastroenterol Suppl       Date:  1985

7.  Effect of intermittent administration of omeprazole on serum pepsinogens in duodenal ulcer patients and healthy volunteers.

Authors:  I Biemond; L F Crobach; J B Jansen; C B Lamers
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

8.  Effect of high dose omeprazole on gastric pepsin secretion and serum pepsinogen levels in man.

Authors:  R W Ten Kate; H A Tuynman; H P Festen; G Pals; S G Meuwissen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.

Authors:  T Lind; C Cederberg; G Ekenved; U Haglund; L Olbe
Journal:  Gut       Date:  1983-04       Impact factor: 23.059

10.  Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects.

Authors:  B Sharma; M Axelson; R P Pounder; P Lundborg; M Ohman; A Santana; M Talbot; C Cederberg
Journal:  Aliment Pharmacol Ther       Date:  1987-02       Impact factor: 8.171

View more
  3 in total

1.  Omeprazole reduces preoperative gastric fluid acidity and volume in children.

Authors:  K Nishina; K Mikawa; N Maekawa; M Tamada; H Obara
Journal:  Can J Anaesth       Date:  1994-10       Impact factor: 5.063

Review 2.  Omeprazole. An update of its pharmacology and therapeutic use in acid-related disorders.

Authors:  M I Wilde; D McTavish
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

3.  Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.

Authors:  H Jenkins; Y Sakurai; A Nishimura; H Okamoto; M Hibberd; R Jenkins; T Yoneyama; K Ashida; Y Ogama; S Warrington
Journal:  Aliment Pharmacol Ther       Date:  2015-02-23       Impact factor: 8.171

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.